Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of six systematic review(s)/meta-analysis(es). ^[1-6]
• Mavacamten significantly improved New York Heart Association (NYHA) class in patients with hypertrophic cardiomyopathy (HCM), with a reduction in NYHA class ranging from 34% to 80% across studies. The pooled analysis showed a significant improvement in clinical response (Log odds ratio (OR) = 0.64, p = 0.00).
• In the hypertrophic obstructive cardiomyopathy (HOCM) subgroup, mavacamten significantly improved the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (standardized mean difference (SMD) = 0.65, 95% confidence interval (CI) 0.44-0.87) and peak oxygen consumption (SMD = 0.49, 95% CI 0.24-0.74), although no significant effect was observed in KCCQ overall (SMD = 0.43, p = 0.08).
• Mavacamten significantly reduced the post-exercise left ventricular outflow tract (LVOT) gradient (p < 0.00001) and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, with three studies confirming the reduction in LVOT gradient.
• No significant differences were observed in the incidence of severe adverse events or treatment-emergent adverse events between mavacamten and placebo.
• Decreased left ventricular ejection fraction was noted in some patients, particularly in the hypertrophic obstructive cardiomyopathy (HOCM) subgroup, where the decrease was significant (SMD = -1.14, 95% CI -1.86 to -0.42).
• Mavacamten demonstrated significant improvements in the HOCM subgroup, including enhanced KCCQ scores (SMD = 0.65, 95% CI 0.44-0.87) and peak oxygen consumption (SMD = 0.49, 95% CI 0.24-0.74), while showing a significant decrease in left ventricular ejection fraction (SMD = -1.14, 95% CI -1.86 to -0.42) in this subgroup. There is no population types or subgroups information available in the reviewed documents for other demographic or comorbid subgroups.